CN115916780A - (9r,13s)-13-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代-1,6-二氢嘧啶-1-基}-3-(二氟甲基)-9-甲基-3,4,7,15-四氮杂三环[12.3.1.02,6]十八-1(18),2(6),4,14,16-五烯-8-酮的晶型 - Google Patents

(9r,13s)-13-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代-1,6-二氢嘧啶-1-基}-3-(二氟甲基)-9-甲基-3,4,7,15-四氮杂三环[12.3.1.02,6]十八-1(18),2(6),4,14,16-五烯-8-酮的晶型 Download PDF

Info

Publication number
CN115916780A
CN115916780A CN202180039763.5A CN202180039763A CN115916780A CN 115916780 A CN115916780 A CN 115916780A CN 202180039763 A CN202180039763 A CN 202180039763A CN 115916780 A CN115916780 A CN 115916780A
Authority
CN
China
Prior art keywords
compound
spectrum
crystalline form
infrared
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180039763.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·K·迪尔格
M·A·加莱拉
D·史密斯
T·M·兹恩巴
D·吕德克
C·西奥拉斯
D·阿乌贾
D·A·J·克雷恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Original Assignee
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Bristol Myers Squibb Co filed Critical Janssen Pharmaceutica NV
Publication of CN115916780A publication Critical patent/CN115916780A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN202180039763.5A 2020-04-10 2021-04-09 (9r,13s)-13-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代-1,6-二氢嘧啶-1-基}-3-(二氟甲基)-9-甲基-3,4,7,15-四氮杂三环[12.3.1.02,6]十八-1(18),2(6),4,14,16-五烯-8-酮的晶型 Pending CN115916780A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008161P 2020-04-10 2020-04-10
US63/008,161 2020-04-10
PCT/US2021/026663 WO2021207659A1 (en) 2020-04-10 2021-04-09 Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one

Publications (1)

Publication Number Publication Date
CN115916780A true CN115916780A (zh) 2023-04-04

Family

ID=75690727

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180039763.5A Pending CN115916780A (zh) 2020-04-10 2021-04-09 (9r,13s)-13-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代-1,6-二氢嘧啶-1-基}-3-(二氟甲基)-9-甲基-3,4,7,15-四氮杂三环[12.3.1.02,6]十八-1(18),2(6),4,14,16-五烯-8-酮的晶型

Country Status (14)

Country Link
US (1) US20230151010A1 (https=)
EP (1) EP4132930A1 (https=)
JP (2) JP2023521411A (https=)
KR (1) KR20230008742A (https=)
CN (1) CN115916780A (https=)
AU (1) AU2021253946A1 (https=)
BR (1) BR112022020243A2 (https=)
CA (1) CA3179957A1 (https=)
CL (1) CL2022002786A1 (https=)
CO (1) CO2022016067A2 (https=)
IL (1) IL297206A (https=)
MX (1) MX2022012523A (https=)
PE (1) PE20231071A1 (https=)
WO (1) WO2021207659A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71692A (fr) 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
KR20250136432A (ko) 2023-02-06 2025-09-16 브리스톨-마이어스 스큅 컴퍼니 밀벡시안 제약 조성물
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795161A (zh) * 2014-10-01 2017-05-31 百时美施贵宝公司 作为因子xia抑制剂的嘧啶酮

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201908467RA (en) * 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795161A (zh) * 2014-10-01 2017-05-31 百时美施贵宝公司 作为因子xia抑制剂的嘧啶酮

Also Published As

Publication number Publication date
EP4132930A1 (en) 2023-02-15
BR112022020243A2 (pt) 2022-11-22
JP2026048873A (ja) 2026-03-17
PE20231071A1 (es) 2023-07-17
IL297206A (en) 2022-12-01
AU2021253946A1 (en) 2022-12-15
WO2021207659A1 (en) 2021-10-14
CO2022016067A2 (es) 2023-01-26
CL2022002786A1 (es) 2023-04-14
MX2022012523A (es) 2022-11-07
JP2023521411A (ja) 2023-05-24
US20230151010A1 (en) 2023-05-18
CA3179957A1 (en) 2021-10-14
KR20230008742A (ko) 2023-01-16

Similar Documents

Publication Publication Date Title
DK2906551T3 (en) CRYSTALLIC FORMS OF A FACTOR XIA INHIBITOR
JP6427551B2 (ja) カリウムイオンチャネル阻害剤としてのピロロトリアジン
CN105916502A (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的固体形式，其组合物和用途
CN115916780A (zh) (9r,13s)-13-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代-1,6-二氢嘧啶-1-基}-3-(二氟甲基)-9-甲基-3,4,7,15-四氮杂三环[12.3.1.02,6]十八-1(18),2(6),4,14,16-五烯-8-酮的晶型
CN107540659A (zh) 四氢异喹啉类化合物、其制备方法、药物组合物及其用途
US20080188517A1 (en) Crystalline forms of a factor xa inhibitor
KR101852226B1 (ko) 오타믹사반의 벤조산염
US7388096B2 (en) Crystalline forms of a factor Xa inhibitor
HK1189584B (en) Benzoic acid salt of otamixaban
HK1212333B (en) Crystalline forms of a factor xia inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination